Ensysce Biosciences, Inc. (ENSC): Cash & Equivalents
$4.31M
As of 2025-12-31
$676.7K
As of 2026-06-30
+11.0%
3-year compound annual growth
+85.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.31M | +23.1% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $3.50M | +211.7% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $1.12M | -64.3% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $3.15M | -74.3% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $12.26M | n/m | 2023-03-30, Balance as of period end |
| 2020-12-31 | $194.2K | n/a | 2022-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $4.31M | +23.1% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $90.0K | -86.7% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $345.1K | -44.9% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $21.82M | -60.8% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $8.24M | -8.5% |
| Immunome Inc. (IMNM) | 2025-12-31 | $653.48M | +355.9% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $37.57M | +31.0% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $16.07M | -16.3% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $13.15M | -50.0% |
Compare ENSC, PRPH, CPHI, KRRO side by side · Screen every company in Pharmaceutical Preparations ↗